Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference

Rhea-AI Summary

Homology Medicines (Nasdaq: FIXX) announced that CEO Albert Seymour, Ph.D., will speak at the 43rd Annual Cowen Healthcare Conference on March 8, 2023, at 10:30 a.m. ET. The event will focus on gene editing and will be streamed live on the company’s website.

Homology is a clinical-stage genetic medicines company dedicated to treating rare diseases through innovative therapies. Its key programs include HMI-103 for phenylketonuria (PKU), HMI-203 for Hunter syndrome, and HMI-102 for adults with PKU. The company is known for its proprietary AAVHSCs vectors that enhance gene delivery.

BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET.

The live webcast presentation will be accessible on Homology’s website in the Investors section, and the webcast replay will be available on the website for 90 days following the presentation.

About Homology Medicines, Inc.
Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines in vivo through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homology’s internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.

Company Contacts:
Cara Mayfield
Vice President, Patient Advocacy
and Corporate Communications
cmayfield@homologymedicines.com
781-691-3510

Investor Contact:
Brad Smith
Chief Financial and Business Officer
bsmith@homologymedicines.com
781-301-7277

FAQ

When will Albert Seymour speak at the Cowen Healthcare Conference for FIXX?

Albert Seymour will speak at the Cowen Healthcare Conference on March 8, 2023, at 10:30 a.m. ET.

Where can I watch the Cowen Healthcare Conference presentation for FIXX?

The live webcast of the presentation will be available on Homology Medicines' website in the Investors section.

What are the key programs of Homology Medicines (FIXX)?

Key programs include HMI-103 for PKU, HMI-203 for Hunter syndrome, and HMI-102 for adults with PKU.

What technologies does Homology Medicines use?

Homology employs AAVHSCs vectors for precise gene delivery and has established a partnership for AAV manufacturing.

What is the focus of Homology Medicines in the healthcare sector?

Homology Medicines focuses on transforming the lives of patients suffering from rare diseases.